The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis

Gil Benedek, Roberto Meza-Romero, Dennis Bourdette, Arthur Vandenbark

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Applying different technologies to monitor disease activity and treatment efficacy are essential in a complex disease such as multiple sclerosis. Combining current assays with flow cytometry could create a powerful tool for such analyses. The cell surface expression level of CD74, theMHC class II invariant chain, is a potential disease biomarker that could be monitored by FACS analysis in order to assess disease progression and the clinical efficacy of partial MHC class II constructs in treatingMS. These constructs, which can bind to and down-regulate CD74 cell-surface expression on monocytes and inhibitmacrophagemigration inhibitory factor (MIF) effects, can reverse clinical and histological signs of EAE. These properties of partial class II constructs are highly compatible with a flow cytometry approach for monitoring CD74 expression as a possible biomarker for disease activity/ progression and as a treatment response marker.

Original languageEnglish (US)
Article numberA002
Pages (from-to)877-884
Number of pages8
JournalMetabolic Brain Disease
Volume30
Issue number4
DOIs
StatePublished - 2015

Fingerprint

Flow cytometry
Multiple Sclerosis
Flow Cytometry
Disease Progression
Biomarkers
Pharmaceutical Preparations
Monocytes
Down-Regulation
Technology
Assays
Monitoring

Keywords

  • CD74
  • EAE
  • Flow cytometry
  • Multiple sclerosis
  • Partial MHC class II constructs

ASJC Scopus subject areas

  • Clinical Neurology
  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis. / Benedek, Gil; Meza-Romero, Roberto; Bourdette, Dennis; Vandenbark, Arthur.

In: Metabolic Brain Disease, Vol. 30, No. 4, A002, 2015, p. 877-884.

Research output: Contribution to journalArticle

@article{10d6f832d33b479fbdac3135cd1a9ece,
title = "The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis",
abstract = "Applying different technologies to monitor disease activity and treatment efficacy are essential in a complex disease such as multiple sclerosis. Combining current assays with flow cytometry could create a powerful tool for such analyses. The cell surface expression level of CD74, theMHC class II invariant chain, is a potential disease biomarker that could be monitored by FACS analysis in order to assess disease progression and the clinical efficacy of partial MHC class II constructs in treatingMS. These constructs, which can bind to and down-regulate CD74 cell-surface expression on monocytes and inhibitmacrophagemigration inhibitory factor (MIF) effects, can reverse clinical and histological signs of EAE. These properties of partial class II constructs are highly compatible with a flow cytometry approach for monitoring CD74 expression as a possible biomarker for disease activity/ progression and as a treatment response marker.",
keywords = "CD74, EAE, Flow cytometry, Multiple sclerosis, Partial MHC class II constructs",
author = "Gil Benedek and Roberto Meza-Romero and Dennis Bourdette and Arthur Vandenbark",
year = "2015",
doi = "10.1007/s11011-014-9634-0",
language = "English (US)",
volume = "30",
pages = "877--884",
journal = "Metabolic Brain Disease",
issn = "0885-7490",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis

AU - Benedek, Gil

AU - Meza-Romero, Roberto

AU - Bourdette, Dennis

AU - Vandenbark, Arthur

PY - 2015

Y1 - 2015

N2 - Applying different technologies to monitor disease activity and treatment efficacy are essential in a complex disease such as multiple sclerosis. Combining current assays with flow cytometry could create a powerful tool for such analyses. The cell surface expression level of CD74, theMHC class II invariant chain, is a potential disease biomarker that could be monitored by FACS analysis in order to assess disease progression and the clinical efficacy of partial MHC class II constructs in treatingMS. These constructs, which can bind to and down-regulate CD74 cell-surface expression on monocytes and inhibitmacrophagemigration inhibitory factor (MIF) effects, can reverse clinical and histological signs of EAE. These properties of partial class II constructs are highly compatible with a flow cytometry approach for monitoring CD74 expression as a possible biomarker for disease activity/ progression and as a treatment response marker.

AB - Applying different technologies to monitor disease activity and treatment efficacy are essential in a complex disease such as multiple sclerosis. Combining current assays with flow cytometry could create a powerful tool for such analyses. The cell surface expression level of CD74, theMHC class II invariant chain, is a potential disease biomarker that could be monitored by FACS analysis in order to assess disease progression and the clinical efficacy of partial MHC class II constructs in treatingMS. These constructs, which can bind to and down-regulate CD74 cell-surface expression on monocytes and inhibitmacrophagemigration inhibitory factor (MIF) effects, can reverse clinical and histological signs of EAE. These properties of partial class II constructs are highly compatible with a flow cytometry approach for monitoring CD74 expression as a possible biomarker for disease activity/ progression and as a treatment response marker.

KW - CD74

KW - EAE

KW - Flow cytometry

KW - Multiple sclerosis

KW - Partial MHC class II constructs

UR - http://www.scopus.com/inward/record.url?scp=84943365257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943365257&partnerID=8YFLogxK

U2 - 10.1007/s11011-014-9634-0

DO - 10.1007/s11011-014-9634-0

M3 - Article

C2 - 25502010

AN - SCOPUS:84943365257

VL - 30

SP - 877

EP - 884

JO - Metabolic Brain Disease

JF - Metabolic Brain Disease

SN - 0885-7490

IS - 4

M1 - A002

ER -